Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

  1. Talukder, R.
  2. Makrakis, D.
  3. Lin, G.I.
  4. Diamantopoulos, L.N.
  5. Dawsey, S.
  6. Gupta, S.
  7. Carril-Ajuria, L.
  8. Castellano, D.
  9. de Kouchkovsky, I.
  10. Jindal, T.
  11. Koshkin, V.S.
  12. Park, J.J.
  13. Alva, A.
  14. Bilen, M.A.
  15. Stewart, T.F.
  16. McKay, R.R.
  17. Tripathi, N.
  18. Agarwal, N.
  19. Vather-Wu, N.
  20. Zakharia, Y.
  21. Morales-Barrera, R.
  22. Devitt, M.E.
  23. Cortellini, A.
  24. Fulgenzi, C.A.M.
  25. Pinato, D.J.
  26. Nelson, A.
  27. Hoimes, C.J.
  28. Gupta, K.
  29. Gartrell, B.A.
  30. Sankin, A.
  31. Tripathi, A.
  32. Zakopoulou, R.
  33. Bamias, A.
  34. Murgic, J.
  35. Fröbe, A.
  36. Rodriguez-Vida, A.
  37. Drakaki, A.
  38. Liu, S.
  39. Lu, E.
  40. Kumar, V.
  41. Lorenzo, G.D.
  42. Joshi, M.
  43. Isaacsson-Velho, P.
  44. Buznego, L.A.
  45. Duran, I.
  46. Moses, M.
  47. Barata, P.
  48. Sonpavde, G.
  49. Wright, J.L.
  50. Yu, E.Y.
  51. Montgomery, R.B.
  52. Hsieh, A.C.
  53. Grivas, P.
  54. Khaki, A.R.
  55. Show all authors +
Journal:
Clinical Genitourinary Cancer

ISSN: 1938-0682 1558-7673

Year of publication: 2022

Volume: 20

Issue: 6

Pages: 558-567

Type: Article

DOI: 10.1016/J.CLGC.2022.08.006 GOOGLE SCHOLAR